INHALED THERAPIES FOR TUBERCULOSIS AND OTHER INFECTIOUS DISEASE

Speakers

 

 

IMG_1616 copy.jpg
Rany Condos
Dr. Rany Condos graduated from Columbia College of Physicians & Surgeons in 1988. She completed her internal medicine residency and was a chief resident at the Presbyterian Hospital of Columbia University. She completed a fellowship in Pulmonary and Critical Care Medicine at New York University School of Medicine. Under the direction of Dr. William N. Rom and Dr. Neil Schluger she began her work with interferon gamma and tuberculosis. This led to funding from the NIH and Doris Duke Charitable Fund and the establishment of an international collaboration and clinical trials. Her interests are in directed immunotherapy in both fibrotic and infectious lung diseases. She is currently Professor of Medicine at New York University School of Medicine where she heads weekly TB conference on the Bellevue Chest Service. She is also, Director of the Adult Cystic Fibrosis Program and Director of the Interstitial Lung Disease/Advanced Lung Disease Program at NYU Health.  She lives in New York with her husband and two children.
Charles Daley.jpg
Charles Daley
CORCORAN_TIM_PHD_PACCM_20130910_.jpg
Timothy Corcoran
Dr. Corcoran is an Associate Professor of Medicine, Bioengineering, and Chemical Engineering in the Division of Pulmonary, Allergy and Critical Care Medicine at the University of Pittsburgh. He completed his Ph.D. in Bioengineering at Carnegie Mellon University in 2000. His primary research interests include aerosol drug delivery and aerosol-based nuclear imaging of the lung. He has been extensively involved in the development of inhaled medications for lung transplant recipients and cystic fibrosis patients and the development special techniques for improving inhaled drug delivery such as the use of low density gases and surfactants to improve drug distribution in the lungs. Dr. Corcoran has developed imaging techniques for quantifying pulmonary physiology including measurements of mucociliary clearance and liquid absorption in the airways. These techniques have been tested in a series of clinical studies involving adult and pediatric patients and will be used to screen new medications for treating lung diseases such as cystic fibrosis.
Screen Shot 2017-08-02 at 9.58.14 AM.png
Larry Schlesinger
Larry S. Schlesinger, MD is an internationally recognized authority in infectious diseases with a particular interest in tuberculosis and lung biology. He earned a BA in Biology from Cornell University and MD from Rutgers Medical School. He completed his residency in Internal Medicine at the University of Michigan and clinical and research fellowships in Infectious Diseases at UCLA. He joined the faculty at the University of Iowa in 1991 where he served as Fellowship Director for the Division of Infectious Diseases and Associate Chair of the Department of Medicine. He moved to the Ohio State University in 2002 where he served as Director of the Division of Infectious Diseases, Department of Internal Medicine until 2011 when he became first chair of Microbial Infection & Immunity. During his tenure he founded the Center for Microbial Interface Biology, a Board of Trustees approved university-wide center with a focus on infectious diseases of concern to public health. In 2017 he became President and CEO of Texas Biomedical Research Institute in San Antonio, TX.

Dr. Schlesinger is a leading physician scientist whose studies focus on the pathogenesis of tuberculosis and other airborne infectious agents that subvert lung immune mechanisms. His discoveries have led to greater insight into the unique attributes that soluble and cellular components of the innate immune system of humans bring to the microbe-host interface (with a focus on human macrophages), translating them into drug discovery platforms. He is a prolific scholar, having authored more than 170 peer-reviewed articles, served as editor of 2 books and has written several chapters in leading textbooks on tuberculosis and lung biology. He has been continually funded for nearly 30 years by the National Institutes of Health (NIH) and other federal agencies as well as private foundations such as the Bill & Melinda Gates Foundation.

He is a current NIH NIAID Council member, Fellow of the American Association for the Advancement of Science, Association of American Physicians and American Academy of Microbiology, and OSU’s 2011 Distinguished Scholar and 2105 COM Distinguished Professor.
Picture1.png
Brian Robertson
Dr Brian D. Robertson is currently Reader in Systems Microbiology in the Medical Research Council Centre for Molecular Bacteriology and Infection at Imperial College London. Dr. Robertson has a BSc (1985) in Zoology from the University of Edinburgh and a PhD (1988) in Parasitology (“Immunobiology of the Excretory-Secretory Antigens of Toxocara canis”) from Imperial College, University of London. He then spent 5 years at the Max-Planck Institut für Biologie in Tübingen, Germany working on LPS biosynthesis in Neisseria gonorrhoeae. On his return to Imperial College London in 1993 he started work on mycobacteria, looking at a range of projects including the development of bioluminescent and fluorescent reporters for in vivo use, trehalose biosynthesis, mycobacterial growth and division, encapsulated drugs and antimicrobial peptides. Dr Robertson is Co-Editor in Chief of the journal “Tuberculosis”, and Director of the Wellcome Trust PhD programme “Molecular and Cellular Basis of Infection”.
JBs passport photo .jpg
Joyoti Basu
Dr. Joyoti Basu is currently Senior Professor and Chairperson of the Department of Chemistry, Bose Institute, India. She has been working in the area of Mycobacterium tuberculosis and its interaction with macrophages for over two decades. She has made significant contributions on understanding how M. tuberculosis subverts host immune defense mechanisms. Her work has been recognized by the Fellowship of India’s three premier science Academies. She has served as Associate Editor of Journal of Immunology and is currently an Academic Editor of PLoS One. She serves as member of the Programme Advisory Committees of the Science and Engineering Research Board, India and the Indian Council of Medical Research. She has reviewed ad-hoc grants of various international grant-giving organizations and reviewed manuscripts for top-ranking international journals such as Nature. Her current interests are focused on the role of epigenetic modifications in tuberculosis infection, focusing on microRNAs and histone modifications.
Joe_Keane.jpg
Joseph Keane
Joseph Keane is a Respiratory Physician at St. James’s Hospital, and Professor in Respiratory Medicine at Trinity College. He completed a clinical and research post-doctoral fellowship in Pulmonary and Critical Care Medicine at Boston University School of Medicine.

Led by Mary O Sullivan, Sally Ann Cryan and Brain Robertson, he is part of a team that seeks to optimize inhaled therapies for tuberculosis (TB) and NTM disease. His research interests include the host immune response to tuberculosis; towards developing improved treatments and vaccines for this disease. His NEJM article on the association of TB reactivation and the use of TNF blockers is the most cited tuberculosis paper since its publication. He is the director of the TB service in St. James’s, which is the designated supra-regional center for tuberculosis. The Health Research Board, Irish Research Council and the Royal City of Dublin Hospital Trust fund Dr. Keane’s research.
Screen Shot 2017-09-15 at 10.51.21 AM.png
Mercedes Gonzalez-Juarrero
Dr. Mercedes Gonzalez-Juarrero is an Associate Professor at the Microbiology, Immunology and Pathology department in the Mycobacteria Research Laboratories at Colorado State University. She completed her PhD at the Universidad Autonoma de Madrid, Spain in 1990. Her primary research interests are to study lack of immune bactericidal effect during pulmonary tuberculosis, aerosol drug delivery of host directed and antimicrobial therapies and development of animal models. She studies the role of pulmonary dendritic and macrophages cell mediated immunity during Mycobacterium tuberculosis infection and has developed animal models to study efficacy of aerosol drug delivery. The ultimate goal of her studies is to develop aerosol therapies against mycobacterial infections that treat drug tolerant and resistant bacilli when combined with chemotherapeutic and immunotherapeutic approaches.

Universidad Complutense, Madrid, Spain BS, Biology (1982)
Universidad Complutense, Madrid, Spain MS, Biology (1985)
USDA-ARS, Plum Island NY, Scholarship from US-Spain Joint Committee for Scientific and Technology Cooperation (1985-1990)
Universidad Autonoma, Madrid, Spain. PhD Immunology-Virology (1990)
ILRAD, Postdoctoral researcher, Nairobi, Kenya (1990-1993)
Postdoctoral Researcher, Colorado State University, Microbiology Immunology and Pathology Department, Mycobacteria Research Laboratories (2001-2003)
Assistant Professor, Colorado State University, Microbiology Immunology and Pathology Department, Mycobacteria Research Laboratories (2003-2009)
Associate Professor, Colorado State University, Microbiology Immunology and Pathology Department, Mycobacteria Research Laboratories (2009-present)
Profile Image
Sally Sharpe
JennyLam.jpg
Jenny Ka Wing Lam
Dr Jenny Lam is currently Associate Professor in the Department of Pharmacology and Pharmacy, The University of Hong Kong. Dr Lam received her degree in Pharmacy from The University of Nottingham, UK (2001). She completed her PhD in drug delivery ('Phosphorylcholine-based copolymer as synthetic vector for gene delivery') at the University of Nottingham (2006) under the supervision of Dr Snow Stolnik. Shortly afterwards, she was awarded the Maplethorpe Fellowship, continued her research in nucleic acid delivery and promoted pharmaceutical education in the Department of Pharmacy at King's College London, UK. In 2009, Dr Lam joined the University of Hong Kong. Her research is focused on the development of novel delivery system for macromolecular therapeutics including nucleic acids, proteins and peptides, and the use of antimicrobial peptides against respiratory infections. She is also interested in using spray drying and spray freeze drying technologies to produce inhaled powder formulation. She has published over 40 scientific articles in pharmaceutics. She is the principal investigator of a number of research projects funded by competitive grants.
0120_0041 (1).jpg
Miriam Braunstein
Miriam Braunstein received her Bachelor of Science degree in Biology from Tufts University, followed by a PhD degree from Princeton University in Molecular Biology. After completing her PhD, she became a Life Sciences Research Foundation Postdoctoral Fellow working at the Albert Einstein College of Medicine in the laboratory of Dr. William Jacobs Jr. It was during her time in Dr. Jacobs’ laboratory that she began studying Mycobacterium tuberculosis, the bacterial pathogen responsible for tuberculosis (TB). Miriam is currently a Professor in the Microbiology and Immunology Department at the University of North Carolina Chapel Hill where she runs an active research program focused on understanding the molecular mechanisms of M. tuberculosis physiology and pathogenesis. Miriam has a long-standing interest in understanding the roles of M. tuberculosis proteins that are secreted into the host environment. Her research includes mechanistic studies of the pathways used by M. tuberculosis to secrete proteins, projects to identify and characterize secreted virulence factors that operate at the host-pathogen interface and efforts to develop M. tuberculosis protein secretion pathways as novel targets for drug development. Finally, she has a long-standing collaboration with Dr. Anthony Hickey (RTI International) to test the efficacy of inhaled therapies for treating TB.
Erik Leuk lab 2016 snij.png
Henderik Frijlink
Erik Frijlink received his pharmaceutical training at the University of Groningen (The Netherlands), where he received his Ph.D. degree in Pharmaceutical Technology and Biopharmacy. He served for two years as a pharmacist in the Martini Hospital (Groningen, Nl). From 1992 to 1997 he worked in the Pharmaceutical Development Department of Solvay Pharmaceuticals. Since 1998 Dr. Frijlink is Professor and Chairman of the Department of Pharmaceutical Technology and Biopharmacy at the University of Groningen. The main interests of his current research are technical and biopharmaceutical aspects of pulmonary drug delivery and the development of dry powder inhalers. Delivery of peptides, proteins and vaccines through pulmonary administration, using stabilizing sugar glasses is a further research topic in his department. Furthermore, he is interested in solid oral dosage forms their technological and biopharmaceutical aspects and gastro-intestinal targeting strategies. Finally, he is interested in development, scale up and quality aspects of pharmaceutical production.
Since 2016 he is Director of the Groningen Research Institute of Pharmacy
Picture1.png
Paolo Colombo
Specializations:

(i) main field: Pharmaceutical technology
(ii) other fields: Drug delivery
(iii) current research interests: Swellable matrices for oral delivery of drugs
Iontophoresis
Nasal and pulmonary administration of drugs
Pharmaceutical micro and nanoparticles

Honors, Awards, Fellowships:

Fellowship "dott. Michele Berta" and "Guglielmina Brughera", 1968
Award for scientific production, University of Pavia, 1973
Foreign correspondent of Ass. Francaise des Enseignants de Pharmacie Galenique,1981
Colorcon Award recipient, 1991
AAPS Fellow, 1996
Outstanding paper Journal of Controlled Release / Jorge Heller Award, 1999
Nominated as Foreign Member of the Academie de Pharmacie Francaise, 1999
Professeur invité, Faculté de Pharmacie de Paris-Sud, France, 2001
Ministery of Health, Expert for evaluation of european mutual recognition dossiers, 2002-
Maurice-Marie Janot Award for Pharmaceutical Sciences, 2004
CRS Reiner Hofmann Award “Product through Science”, 2007
Visiting Professor at Universiti Sains Malaysia, Penang, March, 2009
Honorary Doctorate in Pharmacy from the University of Athens (GR), 2010
Dean of Faculty of Pharmacy, 2010-2012
CRS Founders Award, 2014
IPEC Ralph Shangraw Award, 2014
The University of Salerno’s Seal for Career Achievement Award, 2015

Membership of Professional Societies:

Controlled Release Society, member and past-governor
ADRITELF (Italian Pharmaceutical Technology Teachers), member
SIFEB (Italian Society of Pharmacokinetics and Biopharmaceutics), member
AFI (Industrial Pharmacist Association), member
AAPS (American Association of Pharmaceutical Scientists), member and Fellow
EUFEPS (European Federation Pharmaceutical Scientists), member
APGI (Association Pharmacie Galenique Industrielle), Honorary Member
Profile Image
Amit Misra
Muttil_photo.jpg
Pavan Muttil
Dr. Muttil is an Associate Professor in the Department of Pharmaceutical Sciences at the University of New Mexico, NM, USA. Research in the Muttil laboratory is focused on developing drug and vaccine formulations for inhaled, oral and transdermal delivery systems for infectious diseases and cancers. These novel formulations are evaluated in animal models for their efficacy as a needle-free delivery strategy. Some of the projects being pursued in his laboratory include developing heat-stable vaccines (live bacteria, peptides, VLPs, etc.) in order to have easy accessibility to remote regions of the world; pulmonary immunization against tuberculosis; preclinical lung cancer model development; pulmonary delivery of immunotherapeutic agents for lung cancer; delivery of vaccines using microneedles in preclinical models.
Cipolla-David.jpg
David Cipolla
Dr. Cipolla holds a chemical engineering degree from MIT (S.B.) and UC Davis (M.S.) and a pharmacy degree from the University of Sydney (Ph.D.). Dr. Cipolla currently leads the preclinical research, pharmaceutical sciences and intellectual property efforts at Aradigm Corp and has served in various scientific and technical capacities at Aradigm since 1996. Prior to joining Aradigm, Dr. Cipolla worked at Genentech, Inc. (1988-1996) developing and characterizing the delivery of protein aerosols to the airways, culminating with the approval of Pulmozyme® rhDNase for the management of cystic fibrosis. Dr. Cipolla has contributed in a number of roles on pharmaceutical consortia (including chair of IPAC-RS), academic societies (ISAM board member) and on the editorial board of multiple scientific journals.
Picture1.png
Nicolas Tsapis
After studying Physics at Univ Paris Sud (France), Nicolas Tsapis did his PhD on the influence of proteins on the elastic properties of model biological membranes at Laboratoire de Physique Statistique (ENS, Paris, France). In 2001, he went to Harvard University as a post-doctoral fellow in the groups of Prof. David A. Edwards and Prof. David A. Weitz. There he studied the drying process of droplets containing colloidal particles from a fundamental as well as from an applied point of view. In October 2003, Nicolas Tsapis joined the team of Prof Elias Fattal as a CNRS researcher (Institut Galien Paris-Sud, Univ Paris-Sud, Faculté de Pharmacie, Châtenay-Malabry, France). His research activity focuses on two main topics: Novel contrast agents for medical imaging and theranostics, and spray drying from fundamentals to therapeutic applications. In 2009, he obtained the CNRS bronze medal and in 2014 he was appointed CNRS research director. Together with Prof E. Fattal is the co-leader of the Particle Engineering for Therapeutic applications group at Institut Galien Paris-Sud. He is the author of about 95 publications and 5 patents.
Untitled.png
Francesca Buttini
Francesca is currently holding an Assistant Professor position at the Department of Pharmacy, University of Parma leading a unit dedicated to design and development of pharmaceutical products for inhalation. In 2014, she was appointed as Visiting Lecturer at the Institute of Pharmaceutical Science of King’s College London (UK). In 2016 she has been affiliated as Key Researcher at the Research Center Pharmaceutical Engineering (AT). Furthermore, in 2013 Francesca founded with three colleagues PlumeStars, an innovative Startup, dedicated to development of antibiotic powders for inhalation. She works on the development of innovative pulmonary products. She is an expert on particle engineering, characterization of carrier-based formulations and formulation-device combination.

Up to date, she has published 35 original papers, 5 book chapters and 4 patents in the field of drugs and drug delivery systems.
Profile Image
Anthony Hickey
Profile Image
Bernard Fourie
photo.jpg
Stefano Giovagnoli
Stefano Giovagnoli graduated in chemistry in 1997 at the University of Perugia, Italy. After being R&D scientist at Glaxo Wellcome, Ware, UK, he obtained his PhD in drug microencapsulation and delivery from the University of Perugia, Italy. He was recipient of the 2004 AAPS Outstanding Graduate Student Research Award in Pharmaceutical Technologies. He has been visiting PhD student and postdoc at the School of Pharmacy, University of Kentucky, Lexington, Kentucky. He is currently Associate Professor of Pharmaceutical Technology and Biotechnology at the Department of Pharmaceutical Sciences, University of Perugia. He serves as Board Editor of the Journal of Pharmaceutical Innovation and Journal of Medicinal Chemistry and Research and Review Editor of Frontiers in Pharmacology. He is member of the AAPS, Italian Chemical Society (SCI), AAPS Italian University Network (AItUN), ADRITELF and the Italian CRS chapter. He has about 100 presentations at international meetings, 70 publications, 2 book chapters and 3 patents.
Photo on 2014-03-31 at 20.37 #3.jpg
Edward Nardell
Dr. Nardell is a professor of medicine at Harvard University, based at the Brigham and Women's Hospital, Boston. He is primarily appointed in the Division of Global Health Equity, with a secondary clinical appointment in the Division of Pulmonary and Critical Care Medicine. At Harvard School of Public Health he is appointed in both the Departments of Environmental Health, and Immunology and Infectious Diseases. For more than 25 years he served variously as the tuberculosis control officer for the Departments of Public Health of the Cities of Boston and Cambridge, and for the Commonwealth of Massachusetts. In 1983 he began a lifetime friendship and professional association with Dr. Paul Farmer, co-founder of Partners In Health, (PIH) an NGO working in Haiti, Peru, Russia, Rwanda and many other countries. In 2005 he joined the BWH Division of Global Health Equity to PIH with multidrug resistant TB projects in Peru and Russia, and to be in a position to fund TB transmission control research in South Africa. In 2005, with South African colleagues, he re-established the Riley human to guinea pig transmission model at the globally unique Airborne Infections Research (AIR) Facility near Pretoria. For 10 years Dr. Nardell has been PI of NIOSH, Gates Foundation, USAID and NIH-funded research and implementation projects in South Africa and Peru, and has studied the natural transmission of drug resistant TB, the efficacy of surgical face masks on patients, upper room germicidal air disinfection, inhaled dry-powder colistin, immunization to prevent TB transmission, and most importantly, the rapid impact of effective treatment on drug resistant TB transmission. The later study led to a re-focused approach to TB transmission control called, FAST: Find cases Actively, Separate, and Treat effectively. FAST is being implemented in Bangladesh, Vietnam, Russia, Peru, and several other countries. In collaboration with MEND, an NGO founded by David Edwards, he was PI of a phase I clinical trial of inhaled dry powder capreomycin at BWH. He remains committed to the development of effective inhaled therapies for TB, both as treatment and as transmission control. Dr. Nardell is widely recognized as a world leader in the control of TB transmission – a key factor fueling the global epidemic.
KennethOlivier.png
Kenneth Olivier
Dr. Olivier is a Senior Clinician in the Laboratory of Chronic Airway Infection and Chief of the Pulmonary Branch in the Division of Intramural Research at the National Heart, Lung and Blood Institute, NIH. He received his B.S. in microbiology from Louisiana State University in 1983, his M.D. from Tulane University School of Medicine in 1987, and Master of Public Health in infectious diseases epidemiology from the UNC School of Public Health in 1994. He completed residency training in internal medicine at the United States Air Force Keesler Medical Center in Biloxi, MS, and a fellowship in pulmonary and critical care medicine at the University of North Carolina at Chapel Hill. He served as a pulmonary critical care specialist at the USAF Wilford Hall Medical Center in San Antonio and directed the pulmonary critical care fellowship training program for the San Antonio Uniformed Services Health Education Consortium prior to joining the Laboratory of Clinical Infectious Diseases at the National Institute of Allergy and Infectious Diseases in Bethesda, MD as a staff clinician in 2005. He was recruited to the NHLBI Cardiovascular and Pulmonary Branch in 2014 and tasked with expansion of the pulmonary clinical, training, and research programs. In 2017 he was appointed Chief of the newly formed Pulmonary Branch. He has authored or coauthored more than 125 peer-reviewed research publications, invited review articles, and book chapters and served on the editorial boards of the Journal of Immunology and Chest. His research is focused on pathogenesis and population characteristics of bronchiectasis and chronic airway infection such as the nontuberculous mycobacteria and he has been actively engaged in therapeutics development in these areas.
Profile Image
Gail Cassell
T Hofmann pic.jpg
Thomas Hofmann
Dr. Hofmann is a Pulmonologist and clinical developer of inhaled therapies for severe lung diseases, with over 20 years of experience in Cystic Fibrosis and inhaled drug development. He is the founder and CEO of Qrumpharma, a pharmaceutical startup company with focus on Mycobacterial Pulmonary Disease, starting with NTM (nontuberculous mycobacteria) infections. Over the last decade, he has supported many startup companies and academics in inhaled drug development, under Aumapharma LLC. Prior to that, he served as Chief Medical Officer of Activaero, later became Vectura. Dr. Hofmann was a co-founder of Corus Pharma, Seattle, which became Gilead Sciences in 2006. At Corus Pharma, he was responsible for the clinical development of aerosolized aztreonam (Cayston) for Cystic Fibrosis, and the clinical development of asthma programs.. Dr. Hofmann received his MD and PhD from the University of Giessen, Germany in 1994, and spent his postdoctoral research at the Cystic Fibrosis Center at UNC Chapel Hill. He is a Pediatric Pulmonologist, with broad experience in pulmonary disease, and holds a number of patents on the aerosolized therapy of pulmonary diseases. He is Adjunct Professor at Temple University, Philadelphia, and the 2015 recipient of the Cystic Fibrosis Foundation’s Milton Graub Medical Recognition Award.
Picture1.png
Ruxandra Gref
Ruxandra Gref carries on an interdisciplinary research at the frontier between polymer science, chemical engineering and pharmaceutical technology, mainly focused on the design of drug loaded core-shell nanoparticles to improve the treatment of severe diseases including cancer and microbial infections.
She teaches at a master degree in Paris-Sud University. She is part of the committee of the department of Chemistry in Paris Saclay, in charge with the interdisciplinary research at the interface chemistry-life sciences. Dr Gref is coordinating the “Cyclon Hit” Marie Curie Initial Training Network European project gathering 19 teams in Europe and US. She coordinates also a French ANR network “AntiTBnano” on the topic of engineered nanoparticles to treat tuberculosis.
Dr Gref is partner of a French major project dealing with the treatment of Staphylococcus aureus resistant infections and of an European project dealing with engineered nanoparticles to treat cancer.
Screen Shot 2017-09-12 at 1.55.55 PM.png
Hak-Kim Chan
Hak-Kim Chan, Professor in Pharmaceutics, is leading the Advanced Drug Delivery Group and the Respiratory and Infectious Disease Research Theme at the Faculty of Pharmacy, University of Sydney, Australia. His research focuses on inhalation drug delivery, ranging from aerosol formulation and inhaler device to scintigraphic imaging of lung deposition and clinical outcome. He played a pivotal role in the product development of Pharmaxis’ Aridol and Bronchitol (inhaled mannitol for bronchoprovocation and mucus clearance). His research on pulmonary drug delivery has led to >400 scientific publications (with >10,000 citations) and seven patents. He is an executive editor of Advanced Drug Delivery Reviews, a Fellow of the American Association of Pharmaceutical Scientists and Fellow of Royal Australian Chemical Institute. He served as Vice President of the Asian Federation for Pharmaceutical Sciences.
Top